Keymed Reports Promising Cancer Drug Results

Keymed Biosciences, Inc. (HK:2162) has released an update.

Keymed Biosciences Inc. has shared positive results from a Phase I clinical study of their drug CMG901, a targeted treatment for advanced gastric cancer, at the ASCO Annual Meeting 2024. The study showed promising efficacy with a manageable safety profile for patients with Claudin 18.2-high G/GEJ cancer. Despite the encouraging data, the company cautions shareholders and potential investors that there’s no guarantee for the drug’s successful commercialization.

For further insights into HK:2162 stock, check out TipRanks’ Stock Analysis page.